These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9890264)

  • 1. Immunohistochemical analysis of Fas ligand expression in sarcomas. Sarcomas express high level of FasL in vivo.
    Lee SH; Jang JJ; Lee JY; Kim SY; Park WS; Kim CS; Kim SH; Yoo NJ
    APMIS; 1998 Nov; 106(11):1035-40. PubMed ID: 9890264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
    Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
    Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack.
    O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
    Dis Esophagus; 1999; 12(2):83-9. PubMed ID: 10466039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
    Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
    Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.
    Mitsiades N; Poulaki V; Mastorakos G; Tseleni-Balafouta ST; Kotoula V; Koutras DA; Tsokos M
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2924-32. PubMed ID: 10443700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas.
    Gutierrez LS; Eliza M; Niven-Fairchild T; Naftolin F; Mor G
    Breast Cancer Res Treat; 1999 Apr; 54(3):245-53. PubMed ID: 10445423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas.
    Yoo NJ; Kim HS; Kim SY; Park WS; Park CH; Jeon H; Jung ES; Lee JY; Lee SH
    APMIS; 2003 Mar; 111(3):382-8. PubMed ID: 12752217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
    Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
    World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
    Greil R; Egle A; Villunger A
    Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
    Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
    Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?
    Nagao M; Nakajima Y; Hisanaga M; Kayagaki N; Kanehiro H; Aomatsu Y; Ko S; Yagita H; Yamada T; Okumura K; Nakano H
    Hepatology; 1999 Aug; 30(2):413-21. PubMed ID: 10421649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fas/Fas ligand system and apoptosis induction in testicular carcinoma.
    Schmelz HU; Abend M; Kraft K; Hauck EW; Weidner W; Van Beuningen D; Sparwasser C
    Cancer; 2002 Jul; 95(1):73-81. PubMed ID: 12115319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
    Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
    Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
    J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
    Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
    J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
    O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
    J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transitional cell carcinoma expresses high levels of Fas ligand in vivo.
    Lee SH; Lee JY; Park WS; Kim SY; Jang JJ; Yoo NJ
    BJU Int; 1999 Apr; 83(6):698-702. PubMed ID: 10233582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of Fas (CD95) and FasL (CD95L) immunohistochemical expression suggests Fas/FasL-mediated apoptotic signal is not relevant in cutaneous Kaposi's sarcoma lesions.
    Fernández-Figueras MT; Armengol P; Puig L; Molinero JL; Esquius M; Sirera G; Ariza A
    J Cutan Pathol; 1999 Oct; 26(9):417-23. PubMed ID: 10563496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.